Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer: A randomized, double-blind, placebo-controlled phase II study - CALGB 30504 (Alliance)

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1660-1665

  Ready, Neal E ^a   Pang, Herbert H ^a   Gu, Lin ^a   Otterson, Gregory A ^c   Thomas, Sachdev P ^d   Miller, Antonius A ^b   Baggstrom, Maria ^f   Masters, Gregory A ^g   Graziano, Stephen L ^h   Crawford, Jeffrey ^a   Bogart, Jeffrey ^h   Vokes, Everett E ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d Illinois Oncology Research Association Community Clinical Oncology Program IL Cancer Care   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CHRISTIANA HOSPITAL   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PLACEBO; SUNITINIB; TRIACYLGLYCEROL LIPASE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOCALCEMIA; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLACTIC CRANIAL IRRADIATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMALL CELL LUNG CANCER; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; ETOPOSIDE; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRROLES; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84933521056     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.3105     Document Type: Article

References (29)

1. Travis WD, Travis LB, Devesa SS: Lung cancer. Cancer 75:191-202, 1995 (suppl 1)
2. Miller AA, Herndon JE 2nd, Hollis DR, et al: Schedule dependency of 21 day oral versus 3 day IV etoposide in combination with IV cisplatin in extensive stage small cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B study group. J Clin Oncol 13:1871-1879, 1995
3. Niell HB, Herndon JE 2nd, Miller AA, et al: Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23:3752-3759, 2005
4. Noda K, Nishiwaki Y, Kawahara M, et al: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85-91, 2002
5. Lara PN Jr, Natale R, Crowley J, et al: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530-2535, 2009
6. Hanna N, Bunn PA Jr, Langer C, et al: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038-2043, 2006
7. Schiller JH, Adak S, Cella D, et al: Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593 - A phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 19:2114-2122, 2001
8. Dowell JE, Amirkhan RH, Lai WS, et al: Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2. Anticancer Res 24:2367-2373, 2004
9. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
10. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
11. Motzer RJ, Hutson TE, Tomczak P, et al: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27:3584-3590, 2009
12. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
13. Ready N, Dunphy F, Pang H, et al: Combination chemotherapy with sunitinib (IND74019; NSC 736511) for untreated extensive-stage small cell lung cancer: CALGB 30504 phase 1B safety results. J Clin Oncol 28:528s, 2010 (suppl; abstr 7056)
14. Rubinstein LV, Korn EL, Freidlin B, et al: Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 23:7199-7206, 2005
15. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Cox DR: Regression models and life-tables. J R Stat Soc B 34:187-220, 1972
18. Agresti A: Categorical Data Analysis (ed 2). New York, NY, Wiley, 2002
19. Paz-Ares LG, de Marinis F, Dediu M, et al: PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895-2902, 2013
20. Horn L, Dahlberg SE, Sandler AB, et al: Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006-6011, 2009
21. Ready NE, Dudek AZ, Pang HH, et al: Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol 29:4436-4441, 2011
22. Spigel DR, Townley PM, Waterhouse DM, et al: Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: Results from the SALUTE trial. J Clin Oncol 29:2215-2222, 2011
23. Sharma N, Pennell N, Nickolich M, et al: Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest New Drugs 32:362-368, 2014
24. Ramalingam SS, Belani CP, Mack PC, et al: Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol 5:1279-1284, 2010
25. Arnold AM, Seymour L, Smylie M, et al: Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25:4278-4284, 2007
26. Gitlitz BJ, Moon J, Glisson BS, et al: Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: A Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 5:1835-1840, 2010
27. Han JY, Kim HY, Lim KY, et al: A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer 79:137-142, 2013
28. Schneider BJ, Gadgeel SM, Ramnath N, et al: Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol 6:1117-1120, 2011
29. Spigel DR, Greco FA, Rubin MS, et al: Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung Cancer 77:359-364, 2012